Related Experiment Video

Updated: Aug 11, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+CD38-

E P L M de Grouw, M H G P Raaijmakers, J B Boezeman

    Leukemia
    |February 10, 2006
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
    10:25

    Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

    Published on: August 9, 2019

    Related Experiment Videos

    Last Updated: Aug 11, 2026

    Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
    09:01

    Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

    Published on: March 26, 2018

    Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
    10:25

    Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

    Published on: August 9, 2019

    Related Concept Videos

    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

    Articles linked to this work by shared authors, journal, and citation graph.

    Common Clonal Origin of Core-Binding-Factor AML in Both Donor and Recipient Following Kidney Transplantation.

    Case reports in hematology·2026

    Clonal haematopoiesis associates with distinct cytometric changes of red blood cells and platelets.

    British journal of haematology·2025

    Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

    Leukemia·2024

    Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia.

    Cancer immunology, immunotherapy : CII·2023

    Identification of transcription factors dictating blood cell development using a bidirectional transcription network-based computational framework.

    Scientific reports·2022

    Genetic diversity within leukemia-associated immunophenotype-defined subclones in AML.

    Annals of hematology·2022

    Novel RNA polymerase I and cyclin-dependent kinase combination therapy for the treatment of aggressive acute myeloid leukemia.

    Leukemia·2026

    Measurable residual disease assessment as an early end point of treatment efficacy in acute myeloid leukemia: a multinational PETHEMA study of 2623 patients treated with intensive therapy.

    Leukemia·2026

    Generation of a novel knock-in mouse line expressing oncogenic Kit D814V in the hematopoietic stem cell compartment as a preclinical model for systemic mastocytosis.

    Leukemia·2026

    KT-253, a highly potent and selective MDM2 protein degrader, eliminates malignant myelofibrosis stem/progenitor cells.

    Leukemia·2026

    Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registry.

    Leukemia·2026

    Chronic myeloid leukemia in a global context: confirmatory findings and novel discoveries from a refined Japanese Cohort.

    Leukemia·2026

    Natural Products as Anti-Angiogenic Agents: Molecular Targets, Signaling Pathways, and Mechanistic Insights.

    Current pharmaceutical design·2026

    Outcomes of Percutaneous Transhepatic Biliary Drainage in Patients With Malignant Biliary Obstruction Receiving Palliative Care.

    The American journal of hospice & palliative care·2026

    Resistance to covalent Bruton's tyrosine kinase inhibitors in diffuse large B‑cell lymphoma: Molecular mechanisms and therapeutic implications (Review).

    International journal of oncology·2026

    Anti-RANKL antibody treatment mitigates subchondral bone loss and cartilage degeneration without affecting synovial inflammation in a mouse model of rotator cuff tear arthropathy.

    Bone & joint research·2026

    Spontaneous Tumor Lysis Syndrome in Refractory Metastatic Esophageal Adenocarcinoma Presenting With Septic Shock.

    Cureus·2026

    Chitosan-Coated Oleuropein Nanoliposomes Enable Dose-Sparing Suppression of Serum Inflammatory Markers in a TNF-α-Induced Vascular Inflammation Model.

    ACS omega·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us